24/7 Market News Snapshot 21 October, 2025 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

October 21, 2025

DENVER, Colo., 21 October, 2025 (www.247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. is currently experiencing a bullish trend in pre-market trading as shares are valued at $1.525, representing a notable increase of 9.71% from the previous close of $1.390. This surge is accompanied by a significant trading volume of 1.75 million shares, underscoring strong investor interest and potential momentum. Increased buying pressure suggests that if support is maintained above the $1.50 level, further gains could be on the horizon. Investors are advised to monitor resistance levels and market developments closely to make informed trading decisions.

In addition to its favorable stock performance, Hoth Therapeutics has announced promising advancements in its therapeutic pipeline, particularly relating to HT-KIT, a specialized precision antisense oligonucleotide targeting the KIT gene. This innovative approach aims to treat systemic mastocytosis and other KIT-driven tumors. In preclinical trials, HT-KIT demonstrated over an 80% reduction in KIT expression and a rapid reduction in tumor volume within eight days of treatment, showcasing significant anti-tumor efficacy.

The recent studies have indicated a favorable safety profile, with no dose-limiting toxicities reported thus far. Hoth is advancing its regulatory strategy, having secured FDA Orphan Drug Designation for HT-KIT, which can expedite the development process through exclusive market incentives, tax credits, and fee waivers for therapies targeting rare diseases.

Robb Knie, CEO of Hoth Therapeutics, emphasized the significance of the preclinical results, stating that HT-KIT has the potential to transform treatment for patients with systemic mastocytosis and related conditions. As preparations are made for FDA submission for an Investigational New Drug application, the company aims to initiate a Phase 1/2 dose-escalation study to further evaluate the safety and efficacy of HT-KIT against advanced systemic mastocytosis and select KIT-driven tumors, emphasizing their commitment to innovating targeted therapies with patient safety as a priority.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.